Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Sarcosine Levels Indicate Aggressive Prostate Cancer

By HospiMedica International staff writers
Posted on 18 Feb 2009
A chemical fingerprint called sarcosine can be found in high levels in the urine of men with aggressive cancer of the prostate, providing a potential biomarker of the disease.

One of the most difficult challenges today with regard to prostate cancer is how to determine whether the cancer is aggressive. More...
Physicians tend to over-treat patients with slow-growing cancers.

Investigators examined 1,126 molecules produced by the body in a total of 262 samples of tissue, blood, or urine. They located about 10 molecules (metabolites) that were more often present in samples taken from patients with advanced forms of prostate cancer. One metabolite, sarcosine, was often found at elevated levels in urine samples taken from patients with advanced cancer, or cancer that had spread, but not at all in samples taken from healthy tissue.

By adding sarcosine to cultures, scientists turned benign prostate cells into malignant ones, suggesting that the molecule could play an important role in the development of invasive tumors.

The study was preformed by Arul Chinnaiyan of the University of Michigan Medical School (Ann Arbor, MI, USA) and colleagues. The findings were reported in the February 11, 2009 journal Nature. The authors stress that their results have to be confirmed and calibrated independently before a urine test is for sarcosine can be accepted as a diagnostic tool. The discovery of sarcosine could also open up new pathways for attacking the disease.

Related Links:

University of Michigan Medical School



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.